Latest data on lecanemab to be presented at Alzheimer’s Association International Conference (AAIC) 2023
Stockholm, July 12, 2023 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai will present the latest findings on lecanemab, an anti-amyloid beta (Aβ) protofibril antibody for the treatment of Alzheimer’s disease, at the Alzheimer’s Association International Conference (AAIC). The conference will be held in Amsterdam, the Netherlands and virtually from July 16 to 20, 2023.Key Eisai lecanemab AAIC presentations · Amyloid Reduction and Evidence of Downstream Biomarker ModificationPresentation of results of Aβ, tau, neurodegeneration, gliosis, and imaging biomarkers in the